NDA 208470 · Millicent
Intrarosa
Prasterone · Vaginal
Last checked: Nov 20, 2026Latest source record: Feb 13, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Nov 16, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
95
43 Phase 3, 5 recruiting
FAERS reports
2,752
892 serious, 47 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 17, 2026.
INTRAROSA ® is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. INTRAROSA ® is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. ( 1 )
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 16, 2016 Original approval · Type 2 New Active Ingredient and Type 4 New Combination LabelLetterReview
1 products under this application
- INTRAROSA · PRASTERONE 6.5MG · INSERT, VAGINAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Prasterone" as an intervention, any sponsor and status, largest first.
- Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)Pivotal-lookingCompleted
EndoCeutics Inc.Industry
NCT03287232 · 653 participants · Start Oct 16, 2017 · Primary completion Mar 8, 2019
Drug: Placebo Vaginal Insert; Prasterone 6.5 mg (0.50%) Vaginal Insert · For: Hypoactive Sexual Desire Disorder
Sites: Huntsville, Alabama; Mobile, Alabama; Tucson, Arizona · 69 sites in all
- Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With MenopausePivotal-lookingCompleted
EndoCeutics Inc.Industry
NCT02013544 · 558 participants · Start Feb 2014 · Primary completion Jan 2015
Drug: Placebo; Prasterone (DHEA) · For: Vaginal Atrophy
Sites: Montgomery, Alabama; Tucson, Arizona; Sacramento, California · 38 sites in all
- DHEA Against Vaginal Atrophy - Safety Study of 12 MonthsPivotal-lookingCompleted
EndoCeutics Inc.Industry
NCT01256671 · 530 participants · Start Dec 2010 · Primary completion Jul 2012
Drug: DHEA · For: Vaginal Atrophy
Sites: Montgomery, Alabama; Tucson, Arizona; Sacramento, California · 41 sites in all
- Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal SymptomsPivotal-lookingCompleted
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT01376349 · 464 participants · Start Jul 2011 · Primary completion Aug 2013
Drug: prasterone · For: Breast Cancer; Gynecologic Cancer
Sites: Scottsdale, Arizona; Aurora, Colorado; Boulder, Colorado · 280 sites in all
- Dehydroepiandrosterone (DHEA) Against Vaginal AtrophyPivotal-lookingCompleted
EndoCeutics Inc.Industry
NCT01358760 · 450 participants · Start Jun 2011 · Primary completion Apr 2012
Drug: Placebo; DHEA and 1 more · For: Vaginal Atrophy
Sites: Montgomery, Alabama; Tucson, Arizona; Little Rock, Arkansas · 42 sites in all
- DHEA Versus Placebo in Women With Poor Ovarian ResponsePivotal-lookingStatus unknown
Cairo UniversityAcademic, hospital or other
NCT02561793 · 440 participants (planned) · Start Oct 2015 · Primary completion Sep 2017
Drug: DHEA; Placebo · For: Subfertility
Sites: Cairo, Egypt; Giza, Egypt
- A Clinical Study of INTRAROSA® (Prasterone) Vaginal Inserts in Postmenopausal Vulvovaginal AtrophyPivotal-lookingCompleted
Lee's Pharmaceutical LimitedIndustry
NCT04982692 · 417 participants · Start Sep 13, 2021 · Primary completion Jan 30, 2023
Drug: intravaginal prasterone; Placebo ovules · For: Postmenopausal Vulvovaginal Atrophy
Sites: Shanghai, China
- Does DHEA IVF Outcomes in Poor Responders?Pivotal-lookingSuspended
Homerton University Hospital NHS Foundation TrustAcademic, hospital or other
NCT04066478 · 400 participants (planned) · Start Oct 8, 2017 · Primary completion Dec 31, 2022
Drug: Dehydroepiandrosterone; Placebo · For: Infertility, Female; Poor Response to Ovulation Induction
Sites: London, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use803
- fatigue171
- headache171
- drug ineffective168
- nausea132
- product dose omission issue130
- application site discharge115
- rash95
- dizziness94
- insomnia93
- pain92
- vaginal discharge85
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 4 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 11 |
| 2011 | 35 |
| 2012 | 58 |
| 2013 | 3 |
| 2014 | 6 |
| 2015 | 10 |
| 2016 | 19 |
| 2017 | 24 |
| 2018 | 312 |
| 2019 | 441 |
| 2020 | 301 |
| 2021 | 209 |
| 2022 | 258 |
| 2023 | 300 |
| 2024 | 228 |
| 2025 | 291 |
| 2026 | 228 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Intrarosa (Prasterone (Dhea))
2024 spending
$4.3M
Beneficiaries
3,611
11,112 claims
Per beneficiary
$1,193
$9.27 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,707,916 |
| 2021 | $3,774,126 |
| 2022 | $3,802,825 |
| 2023 | $3,782,382 |
| 2024 | $4,306,828 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis.
Comini ACM, Carvalho BM, Moreira MJB, et al. · Clin Breast Cancer 2023 · Meta-Analysis, Systematic Review
- Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause.
Labrie F, Archer DF, Martel C, et al. · Menopause 2017 · Randomized Controlled Trial
- Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator.
Montesino M, Labrie F, Archer DF, et al. · Gynecol Endocrinol 2016 · Clinical Trial, Phase III, Randomized Controlled Trial
- Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2006 · Clinical Trial
- Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
Labrie F, Archer DF, Bouchard C, et al. · Maturitas 2015 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
Sánchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, et al. · J Rheumatol 2008 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Millicent
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.